Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.03, Zacks reports. Fresenius SE & Co. had a return on equity of 10.25% and a net margin of 6.67%.
Fresenius SE & Co. Stock Up 5.5%
Shares of Fresenius SE & Co. stock traded up $0.76 during midday trading on Wednesday, reaching $14.36. 33,390 shares of the company’s stock traded hands, compared to its average volume of 167,336. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.97 and a current ratio of 1.28. Fresenius SE & Co. has a 52 week low of $10.33 and a 52 week high of $17.60. The company’s 50 day simple moving average is $12.89 and its 200 day simple moving average is $12.86. The company has a market cap of $32.35 billion, a price-to-earnings ratio of 18.18 and a beta of 0.63.
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on the stock. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a report on Tuesday, July 21st. Citigroup restated a “buy” rating on shares of Fresenius SE & Co. in a research note on Wednesday, October 28th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Fresenius SE & Co. in a research report on Thursday, August 6th. Three equities research analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy”.
Get Our Latest Stock Analysis on Fresenius SE & Co.
Fresenius SE & Co. Company Profile
Fresenius SE & Co KGaA is a Germany-based global health care group that develops and provides products, services and technologies for hospitals, clinics and patients. The company’s activities are focused primarily on health care products and therapies, as well as the operation of hospitals and other medical facilities.
Fresenius Kabi, one of the company’s core businesses, supplies medicines and therapies for critically and chronically ill patients, including intravenous drugs, clinical nutrition, infusion therapies, medical devices and related services.
Further Reading
- Five stocks we like better than Fresenius SE & Co.
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
- Washington Made a $2 Billion Quantum Bet, But Can Either ETF Match It?
Receive News & Ratings for Fresenius SE & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
